2010CCO 晚期非小细胞肺癌一线全身化疗
2010CCO First-line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
2010-01-01
New Doublet Therapy1. When using a platinum-based combination, a recommendation is made in favour of combining a new agent with the platinum agent on the basis of modest improvements in survival. This recommendation is consistent with those of other guidelines.2. It is recommended that a platinum agent be added to a new chemotherapy drug for suitable patients. This recommendation places a higher value on improved survival than on increased toxicity.3. There is no convincing evidence that any new agent in combination with platinum is superior to any other platinum plus new-agent combination. The available data are not sufficiently compelling to recommend the use of docetaxel or gemcitabine over other new agents. When selecting a platinum and new chemotherapy regimen, consideration should be given to toxicity, convenience, and cost.4. A recommendation is made in favour of combining a platinum agent with a new drug over using pairs of new agents. This recommendation places a greater value on the probable modest increase in survival over increases in toxicity.5. For patients receiving platinum-based doublet therapy, a recommendation in favour of cisplatin over carboplatin is made based on a possible modest improvement in survival and an improvement in response. However, given the poor prognosis in this population, the relative toxicities and quality of life (QOL) differences should be given strong consideration.Triplet Therapy
